RxDoctor Payments Data

John Lunsford, MD

Family Medicine · Hanover, PANPI 1013916899

Payments from drug & device makers

$12,417in general payments, 2019–2025

Across 863 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • GSK$873
  • Lilly USA, LLC$663
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$12,395100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,417 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$161,693
Medicare patients
250
Services billed
3,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$138,897
NuplazidPimavanserin Tartrate14$69,049
OzempicSemaglutide39$65,121
XareltoRivaroxaban30$41,612
JardianceEmpagliflozin35$35,133
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,684
TrulicityDulaglutide21$22,528
JanuviaSitagliptin Phosphate15$20,606
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$17,408
RybelsusSemaglutide13$17,163
LinzessLinaclotide20$13,329
Breo ElliptaFluticasone/Vilanterol18$7,031
Atorvastatin Calcium644$4,239
SynthroidLevothyroxine Sodium54$3,788
Losartan Potassium469$3,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,012$138,897158 claims
Novo NordiskOzempic, Rybelsus$1,558$82,28552 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$873$52,12373 claims
Johnson & JohnsonXarelto$157$41,61230 claims
Boehringer IngelheimJardiance$429$35,13335 claims
Lilly USA, LLCTrulicity$663$22,52821 claims
MerckJanuvia$303$20,60615 claims
AbbVieLinzess, Synthroid$2,358$17,11774 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →